Zhimeng Biopharma completes patient enrollment for ALS trial
Shanghai-based Zhimeng Biopharma has finalized patient recruitment for its Phase 2/3 clinical trial of the drug candidate CB03-154, designed to treat ALS.
Zhimeng Biopharma has announced the completion of patient enrollment for its pivotal Phase 2/3 clinical trial of CB03-154, a potassium channel opener intended to treat amyotrophic lateral sclerosis (ALS). The milestone allows the company to transition fully into the data collection and evaluation phase of the study.
The trial aims to determine the efficacy and safety profile of CB03-154 in patients suffering from the neurodegenerative disease. By merging the Phase 2 and Phase 3 segments, the company seeks to streamline the clinical development process required for potential regulatory submission.
ALS remains a condition with few effective treatment options, driving significant demand for new pharmacological interventions. The results from this trial will be central to determining whether CB03-154 offers a viable therapeutic path forward for patients diagnosed with the condition.